To examine biochemical control, survival, and late morbidity with definitive low-dose-rate brachytherapy (LDR-BT) for patients with prostate cancer surviving for >10 years after treatment.
Introduction
Low-dose-rate brachytherapy (LDR-BT) is a highly effective minimally invasive treatment for organ-confined prostate cancer. It can be offered as a monotherapy for low-risk disease, or in conjunction with external beam radiotherapy (EBRT) and/or androgen-deprivation therapy (ADT) for intermediateand high-risk disease. The slow natural history of prostate cancer means that late disease recurrence at ≥10 years after treatment is not uncommon [1] . However, robust data on long-term biochemical control and survival beyond 10 years of follow-up after LDR-BT are limited, but needed.
Few groups analysing the effectiveness of definitive LDR-BT followed their patients for a median of ≥10 years [2] [3] [4] [5] . As the choice of definitive therapy in the context of prostate cancer is often driven by patient's knowledge of long-term toxicity profile of a recommended treatment, data on late sequelae of LDR-BT beyond the first decade of follow-up become essential.
Given the paucity of published reports on long-term effectiveness and safety of LDR-BT for ≥10 years after implantation, we sought to examine biochemical control, survival, and late morbidity with permanent interstitial BT in patients with low-, intermediate-, and high-risk prostate cancer at >10 years of follow-up. Additionally, we aimed to characterise prognostic factors for biochemical failure-free survival (BFFS) and overall survival (OS) in this subset of patients.
Patients and Methods

Patient Selection
The present investigation was a prospective cohort analysis. Approval by our Institutional Review Board was obtained before initiating the study. We identified 757 men with organconfined prostate cancer who underwent definitive LDR-BT, with or without EBRT, at our institution between 1990 and 2006, and were followed prospectively for >10 years. All patients were categorised as low-, intermediate-, or highrisk according to the National Comprehensive Cancer Network (NCCN) criteria [6] . Patients who also received ADT, consisting of a LHRH analogue with or without antiandrogen, were included in the analysis. ADT was administered for 6 months to the intermediate-risk patients and ≥9 months to the high-risk patients. Earlier in the study, low-risk patients were also prescribed ADT, for 3-6 months, with the goal of prostate size reduction if it measured >50 mL. For analysis of late morbidities, we limited our cohort only to patients with documented AUA IPSS, the Quality-of-Life Scale (QoL) score, and our institution's fourpoint Sexual Potency Scale (SPS) score at baseline and last follow-up. 1999) . Post-implant dosimetry with the goal to calculate the biologically effective dose (BED) was conducted within 30 days after implantation, as previously described [7] . EBRT was delivered either 6-8 weeks after LDR-BT or 3-4 weeks before LDR-BT using conventional fractionation to a total dose of 45 Gy. A three-dimensional conformal technique was used initially, which was switched to intensity modulated/ image-guided RT more recently.
All patients were followed every 6 months for the first 5 years, and then annually in the subsequent years. PSA measurement was obtained at every visit. Biochemical failure (BCF) was defined as a PSA level increase by ≥2 ng/mL above the nadir PSA [8] . Distant metastases were documented either by imaging and/or biopsy.
Morbidity Data
The IPSS was used to assess urinary function. The sevenpoint delighted-terrible QoL questionnaire was used to evaluate QoL due to urinary symptoms, with the score of 0 describing 'delighted', 3 -'mixed', 6 -'terrible' QoL. The four-point SPS was used to document sexual function, with the score of 0 describing 'no erection', 1 -'erection inadequate for penetration', 2 -'erection adequate for penetration but suboptimal', and 3 -'excellent erection'. In morbidity analysis, 'potent' was defined as a patient with an SPS score of 3. IPSS, QoL and SPS scores were collected by the physician at initial consultation and at each follow-up after implantation. For this analysis, only scores before treatment and at last follow-up were recorded.
Statistical Analysis
The endpoints of the study were BFFS, distant metastases-free survival (DMFS), prostate cancer-specific survival (PCSS), and OS. The survival interval was calculated from the date of implantation or the last day of definitive EBRT to the date of last contact or first occurrence of the event of interest. Survival estimates with corresponding 95% CIs were measured for the study endpoints using the Kaplan-Meier method. The log-rank test was used to compare distributions of BFFS, DMFS, PCSS, and OS stratified by NCCN-defined risk groups.
Multivariable Cox proportional-hazards models were used to identify factors associated with BFFS or OS. Estimates of corresponding hazard ratios (HRs) and 95% CIs were calculated. The following prognostic factors were included in the Cox proportional-hazards models: age, race, significant smoking history, alcohol use, diabetes, hypertension, coronary artery disease (CAD), heart disease (other than CAD), other cancer, past surgical history, stage, Gleason score, pretreatment PSA level, NCCN risk group, type of isotope, receipt of EBRT, total BED, receipt of ADT, duration of ADT, and pre-implant prostate volume. The proportionalhazards assumption was checked graphically using log-log survival. Chi-squared analysis was used to assess differences in patient's baseline characteristics between the risk groups, and to analyse changes in morbidity scores between initial presentation and last follow-up. Hypothesis testing was twosided and conducted at the 5% level of significance. All statistical analyses were performed using StataIC, version 14 (StataCorp LP, College Station, TX, USA).
Results
Baseline Characteristics
In all, 370 (48.9%) patients had low-, 170 (22.5%) intermediate-, and 217 (28.6%) high-risk disease (Table 1) . Intermediate-risk patients had mostly stage T1a-T2a (65.3%), whereas high-risk patients had mostly stage T2b-T2c (72.4%) disease. Gleason score <7 and pre-treatment PSA level of <10 ng/mL constituted 73.6 and 74.5% of cases, respectively. Only 9.2% of patients had a Gleason score of ≥8 at diagnosis, and only 7.3% had a PSA level of >20 ng/mL. A total of 26.8% patients received supplemental EBRT and 50.1% also received ADT, for a median of 6 months. Of 379 patients who were prescribed ADT, 367 (97%) received it for a total 782 © 2018 The Authors BJU International © 2018 BJU International of ≤9 months. The median age at diagnosis was 65 years. Most of the patients had no history of smoking (69.1%) or alcohol abuse (69.9%). Most men had no major comorbidities, including diabetes, hypertension, CAD, heart disease, or history of another cancer.
Treatment Outcomes
The median (range) follow-up was 12.5 (10.1-21.8) years. At the time of analysis, 88.6% of patients were alive, 1.5% died from prostate cancer, and 13.9% developed BCF, with most failures (82%) occurring in the first decade of follow-up ( Table 2 ). The median time to BCF was 7.4 years. Most BCFs occurred amongst the high-risk patients (53%). Overall, 2.3% of patients developed distant metastases, 35% of which occurred in the second decade of follow-up.
The overall 17-year rates for BFFS, DMFS, PCSS, and OS were 79, 97, 97, and 72%, respectively (Table 3) . When stratified by the NCCN risk group, the 17-year BFFS rate for low-, intermediate-, and high-risk disease was 86, 80, and 65%, respectively(P < 0.001), whereas the OS rate for the same groups was 82, 73, and 60%, respectively (P = 0.09).
In a further analysis, intermediate-and high-risk patients were combined in a single group and compared with low-risk disease. Kaplan-Meyer survival curves for low-risk vs combined 'higherrisk' cohorts are shown in Fig. 1 . For the low-risk vs combined 'higher-risk' cohorts the 17-year rates for BFFS were 86 vs 72% (P < 0.001), DMFS 98 vs 97% (P = 0.32), PCSS 98 vs 96% (P = 0.29), and OS 82 vs 62% (P = 0.09). 
Prognostic Factors for BFFS and OS
Morbidity Analysis
A total of 581 of 757 patients (76.7%) had documented IPSS, QoL, and SPS scores at baseline and last follow-up, and were included for morbidity analysis (Table 5 ). There was a significant decline in sexual function for the entire cohort: of those patients who were potent at baseline (n = 320) only 25% remained potent by the last follow-up. When stratified by NCCN risk group, the proportion of men reporting 'excellent' sexual function decreased from 55.5% before treatment to 16.8% at the last follow-up in the low-risk group, from 60.3 to 12.2% in the intermediate-risk group, and 
Discussion
To the best of our knowledge, this is to date the largest prospective cohort analysis of clinical outcomes with permanent interstitial prostate BT >10 years after implantation. LDR-BT yielded robust long-term biochemical control and survival rates, with a 17-year BFFS rate of 79% and PCSS rate of 97%. Older age at diagnosis and stage T3a-3b disease predicted worse OS. Receipt of ADT appeared to provide no survival advantage, but was associated with improved BFFS. Urinary symptoms and QoL were mainly unaffected at >10 years after LDR-BT, although there was a marked decline in sexual function. Not surprisingly, most men surviving beyond the first decade of follow-up were aged ≤70 years at diagnosis and had no significant co-morbidities or history of substance abuse.
When compared with available data on long-term cancerspecific survival after radical prostatectomy (RP), LDR-BT appears to be an effective alternative. For instance, a Johns Hopkins University series of 2404 men with localised prostate cancer treated with RP revealed an actuarial 15-year PCSS rate of 90% at a mean follow-up of 6.3 years [9] . At the same time, the Scandinavian Prostate Cancer Group 4 (SPCC4) trial comparing RP vs observation in localised prostate cancer, recorded only 18% of deaths from prostate cancer amongst patients treated with RP at 18 years of follow-up [10, 11] . In the Prostate Cancer Intervention Versus Observation Trial (PIVOT) of localised prostate cancer treated with surgery vs observation, deaths from prostate cancer accounted for 5.8% of all RP cases at a median followup of 10 years [12] . Whilst such comparisons of long-term outcomes of LDR-BT with RP are suboptimal given heterogeneity of patient populations and inherent selection and treatment bias, conducting a large randomised study of the effectiveness of permanent interstitial brachytherapy vs surgery presents a significant challenge. The only phase III trial comparing BT and RP, titled the American College of Surgeons Oncology Group (ACOSOG) Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial (SPIRIT), closed after 2 years due to poor accrual [13] . Another randomised study comparing BT and RP, Surgery Against Brachytherapy -a Randomised Evaluation (SABRE), also closed early due to poor accrual, and analysis was not feasible due to a very small sample size [14] .
The late morbidity with LDR-BT that we observed in the present analysis appears to compare fairly well with late morbidity documented in RP studies. The investigators of the SPCC4 trial reported an erectile dysfunction prevalence of 84% after RP at a median follow-up of 12.2 years [15] . However, this was only marginally higher than the prevalence amongst the observed patients (80%), 67.4% of whom also received ADT. Such a finding highlights that development of chronic erectile dysfunction issues amongst a high proportion of patients with prostate cancer is multi-factorial in aetiology, and is likely a result of not only RP or BT adverse effects, but also of the impact of ADT, physiological ageing, and/or other co-morbid conditions [11, 16] . With regards to the urinary toxicities, the SPCC4 trial revealed a prevalence of urinary leakage amongst 41% patients in the RP cohort and 11% in the watchful-waiting cohort. In the present study, 46.1% patients had moderate-to-severe urinary symptoms (IPSS ≥8) by the last follow-up. However, we must acknowledge that the IPSS system does not include urinary incontinence in its assessment of urinary toxicities, therefore particular caution should be taken when interpreting such a comparison. Interestingly, the prematurely closed SPIRIT trial noted improved urinary symptoms and sexual function with BT when compared with RP [13] . However, the follow-up in the SPIRIT trial was only 5.2 years. I-BT monotherapy and reported a 15-year BFFS rate of 80.4% at a median follow-up of 11.7 years. The corresponding 15-year rate in our present analysis was 84%. It is worth noting that in the Sylvester et al. [3] study, none of the patients received ADT, or EBRT. Also, most of the patients (73.5%) were lowrisk by D'Amico risk group classification and only 5.1% had high-risk disease.
The present study shows that 18% of patients with biochemical relapse and 35% with distant recurrence fail at >10 years after treatment. These data parallel findings of another large retrospective analysis of 675 patients treated with LDR-BT, with or without ADT, which documented a total of 26% of all relapses in the second decade after implantation [4] . Therefore, it is essential that physicians treating these patients counsel them on the possibility of late disease recurrence at >10 years after treatment and discuss the importance of continued follow-up.
The effects of LDR-BT on sexual function are more gradual than with RP, therefore studies with longer follow-up are important in documenting incidence of this significant toxicity [4, [18] [19] [20] [21] . In a University of Washington analysis of 226 patients with prostate cancer treated with permanent BT, the 7-year actuarial rate of potency preservation was 55.6% at a median follow-up of 6.4 years [20] . Younger non-diabetic patients with better pre-treatment scores were more likely to preserve potency. In the present study, with a median followup of 12.4 years, out of 320 patients who reported 'excellent' sexual function at diagnosis, only 79 (25%) did so at their last clinic visit. Given the extended follow-up of the present study cohort, as well as receipt of ADT by 50.1% and EBRT by 26.8% of the patients, a marked decrease in potency is not surprising. Furthermore, such a low potency rate at the last clinic visit could be partially explained by misreporting of abstinence as erectile dysfunction by some patients.
The present analysis did not find an OS benefit with ADT (P = 0.74). This may in part be explained by the fact that the present cohort represents a very unique patient population, with potentially less aggressive disease. In fact, 90% of patients in the present study had a Gleason score of ≤7, 92% had a pre-treatment PSA level of ≤20 ng/mL, and 98% had stage ≤T2c. At the same time, in the present analysis we found a 59% reduction in the risk of BCF with receipt of ADT (P = 0.009) by patients who underwent LDR-BT as monotherapy. Longer duration of hormonal therapy (>6 months) did not provide additional benefit. In the recent American Brachytherapy Society Task Group Report on the use of ADT with prostate BT, the authors reviewed 52 studies with a total of 43 303 patients treated with BT and hormonal agents [22] . Overall, they noted a lack of BFFS benefit with addition of ADT to BT in 71% and improvement in 28% of the studies. Notably, none of the reviewed studies showed an OS benefit, with three studies reporting worse OS. The American Brachytherapy Society review should be interpreted with some caution, given heterogeneity of studies and treatment biases. However, taking into account long-term toxicities with hormonal therapy, lack of documented survival benefit, and higher mortality in certain demographic groups [23] , special care should be taken to identify those patients for whom ADT in addition to LDR-BT is unlikely to be therapeutic and should be omitted.
The present study has several important shortcomings. First, no morbidity data from the last follow-up were available for 23% (176/757) of all patients, hence it is possible that some of the reported incidences of urinary or sexual dysfunction, or QoL, were either over-or under-estimated. Additionally, we did not collect information on the use of phosphodiesterase-5 agents, which partially limits our conclusions regarding sexual function of the patients at the last follow-up. Furthermore, our present data did not include assessment of long-term rectal morbidity, which is not uncommon after LDR-BT [24] . Also, we were unable to obtain data on the proportion of patients who had received ADT for prostate size reduction before BT, which may be an important factor when counselling patients on the choice of definitive therapy for their prostate cancer (LDR-BT vs surgery). Furthermore, given the extended overall period of patient accumulation, our treatment regimens underwent several changes over the years: e.g., for intermediate-risk patients we went from monotherapy alone to hormonal therapy and implantation, and then, with the success of combined treatment we incorporated EBRT into the treatment modality for both intermediate-and high-risk patients. Therefore, it is possible that rates for biochemical control and survival for intermediate-risk patients were underestimated due to potentially suboptimal treatment. Lastly, some caution should be exercised when applying findings of the present study to a more general practice, as all implants in this cohort were performed by the same physician with long-term experience in prostate LDR-BT.
In summary, LDR-BT is a safe and effective alternative to RP for a well-selected patient population. It yields superb survival rates, with a 17-year PCSS rate of 97%. Notably, 18% of patients with biochemical relapse will fail at >10 years after treatment, which justifies their continued follow-up. Urinary function and QoL at >10 years after LDR-BT appear to be very favourable.
